Beijing Green Bamboo Delivery Table Exchange, with three clinical stages in research products

On June 29, Capital State learned that Beijing Green Bamboo Biotechnology Co., Ltd. (Beijing Green Bamboo) submitted a prospectus to the Hong Kong Stock Exchange on June 28, intending to be listed on the motherboard. CICC is an exclusive sponsor.

Beijing Green Bamboo is a biotechnology company dedicated to providing quality and cheap human vaccines and therapeutic biological agents to prevent and control infectious diseases and solve the main medical needs that have not met cancer and autoimmune diseases.

As of the last actual possible date, the company's product pipeline includes three clinical stages of research products, including core products LZ901 and K3, and four clinical pre -clinical research products.

LZ901 is the company's core product and independent development of the reorganized band -shaped shingle candidate vaccine. It is expected to become the world's first shingles vaccine with tetraphor molecular structure to prevent adult chickenpox belt -shaped herpes virus ("" "" "" Vzv ") Zessy caused.

K3 is the company's core product and independent development of the reorganized human anti-TNF-α monoclonal antibody injection. Arthritis, ankylosing cylindritis and plaques -like psoriasis.

It is worth noting that Beijing Green Bamboo does not have any products that have been allowed to sell for commercial sales, nor does it generate any benefits from product sales.

The prospectus shows that in the first quarter of 2020, 2021 and 2022, the company's other revenue was 4.978 million yuan, 6.896 million yuan and 3.575 million yuan, respectively; the total loss and comprehensive expenditure during the year were 174 million yuan, 539 million yuan, and 4429.7. 10,000 yuan.

During the period, R & D expenditure was 15.665 million yuan, 42.983 million yuan and 21.748 million yuan.

Beijing Green Bamboo stated that it is planned to use the IPO raised funds mainly for clinical development, manufacturing and commercialization of core products; mainly for the clinical development and manufacturing of K193; Manufacturing; the construction and further expansion of R & D capabilities for the construction of the second phase of Zhuhai, because the company is using the opportunity to build another R & D facility in Beijing; it is used for operating funds and other general companies.

- END -